Psilera Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$8.8M
- Investors
-
12
Psilera General Information
Description
Developer of psychedelic-based drugs designed for neurological therapeutics. The company's proprietary neuromodulator pipeline is developed by repurposing psychoactive natural products as building blocks for next-generation therapies to improve mental health, enabling clinicians to treat cognitive, mood, and substance use disorders.
Contact Information
Website
www.psilera.comCorporate Office
- 3201 West Hillsborough Avenue
- Suite 151868
- Tampa, FL 33614
- United States
Corporate Office
- 3201 West Hillsborough Avenue
- Suite 151868
- Tampa, FL 33614
- United States
Psilera Timeline
Psilera Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 28-May-2026 | $8.8M | Completed | Pre-Clinical Trials | ||
| 6. Grant | 15-Sep-2025 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 05-Sep-2024 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 30-Sep-2023 | Completed | Startup | |||
| 3. Seed Round | 01-Jul-2021 | Completed | Startup | |||
| 2. Accelerator/Incubator | 09-Jul-2020 | $50K | $240K | Completed | Startup | |
| 1. Capitalization | 01-Jan-2020 | $190K | $190K | Completed | Startup |
Psilera Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Psilera Patents
Psilera Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024275806-A1 | Formulations containing tryptamine derivatives and uses thereof | Pending | 24-May-2023 | ||
| EP-4720039-A2 | Formulations containing tryptamine derivatives and uses thereof | Pending | 24-May-2023 | ||
| US-20260306453-A1 | Formulations containing tryptamine derivatives and uses thereof | Pending | 24-May-2023 | ||
| WO-2024243488-A2 | Formulations containing tryptamine derivatives and uses thereof | Inactive | 24-May-2023 | ||
| WO-2024243488-A3 | Formulations containing tryptamine derivatives and uses thereof | Inactive | 24-May-2023 | A61K31/4045 |
Psilera Signals
Psilera Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government | |||
| University of South Florida | University | |||
| Bonaventure Equity | Venture Capital | Minority | ||
| Frühstarter Ventures | Angel Group | Minority | ||
| Mystic Ventures | Venture Capital | Minority |
Psilera FAQs
-
When was Psilera founded?
Psilera was founded in 2019.
-
Where is Psilera headquartered?
Psilera is headquartered in Tampa, FL.
-
What is the size of Psilera?
Psilera has 10 total employees.
-
What industry is Psilera in?
Psilera’s primary industry is Drug Discovery.
-
Is Psilera a private or public company?
Psilera is a Private company.
-
What is Psilera’s current revenue?
The current revenue for Psilera is .
-
How much funding has Psilera raised over time?
Psilera has raised $16.2M.
-
Who are Psilera’s investors?
U.S. Department of Health and Human Services, University of South Florida, Bonaventure Equity, Frühstarter Ventures, and Mystic Ventures are 5 of 12 investors who have invested in Psilera.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process